2020
Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism
Minisola S, Arnold A, Belaya Z, Brandi ML, Clarke BL, Hannan FM, Hofbauer LC, Insogna KL, Lacroix A, Liberman U, Palermo A, Pepe J, Rizzoli R, Wermers R, Thakker RV. Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism. Journal Of Bone And Mineral Research 2020, 37: 2315-2329. PMID: 36245271, PMCID: PMC10092691, DOI: 10.1002/jbmr.4665.Peer-Reviewed Original ResearchConceptsPrimary hyperparathyroidismFamilial hypocalciuric hypercalcemiaMultiple endocrine neoplasia syndromeCalcium-containing kidney stonesIntestinal calcium hyperabsorptionMore parathyroid glandsParathyroid hormone levelsAsymptomatic primary hyperparathyroidismCalcium-sensing receptorEndocrine neoplasia syndromeNeonatal severe hyperparathyroidismHyperparathyroidism-jaw tumor syndromeJaw tumor syndromeCalcium hyperabsorptionPostmenopausal womenSevere hyperparathyroidismParathyroid hormoneSerum calciumHypocalciuric hypercalcemiaPathophysiologic basisParathyroid cellsParathyroid glandsHormone levelsFiltered loadMetabolic factors
2018
Primary Hyperparathyroidism
Insogna KL. Primary Hyperparathyroidism. New England Journal Of Medicine 2018, 379: e43. PMID: 30575486, DOI: 10.1056/nejmc1813648.BooksPrimary Hyperparathyroidism
Insogna KL. Primary Hyperparathyroidism. New England Journal Of Medicine 2018, 379: 1050-1059. PMID: 30207907, DOI: 10.1056/nejmcp1714213.Books
2007
The Role of the Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin Cytokine System in Primary Hyperparathyroidism
Nakchbandi IA, Lang R, Kinder B, Insogna KL. The Role of the Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin Cytokine System in Primary Hyperparathyroidism. The Journal Of Clinical Endocrinology & Metabolism 2007, 93: 967-973. PMID: 18073309, PMCID: PMC2266956, DOI: 10.1210/jc.2007-1645.Peer-Reviewed Original ResearchConceptsNuclear factor-kappaB ligandPrimary hyperparathyroidismBone lossReceptor activatorTotal femurIL-6Bone resorptionIL-6 soluble receptorMild primary hyperparathyroidismBone mineral densitySoluble receptor activatorMechanism of actionIL-6sRSRANKL levelsSerum levelsBone turnoverMineral densityCytokine systemSoluble receptorHyperparathyroidismNormal rangeSkeletal responsivenessBiochemical markersPatientsGreater risk
2002
Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women.
Insogna K, Mitnick M, Pascarella J, Nakchbandi I, Grey A, Masiukiewicz U. Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women. Journal Of Bone And Mineral Research 2002, 17 Suppl 2: n108-16. PMID: 12412787.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnimalsBone and BonesBone ResorptionCollagenCollagen Type ICytokinesDisease Models, AnimalEstrogensFemaleFollow-Up StudiesHumansHyperparathyroidismInterleukin-6MenopauseMiceMiddle AgedOsteoporosis, PostmenopausalParathyroid HormonePeptidesPostmenopausePredictive Value of TestsPremenopauseReceptors, Interleukin-6Reference ValuesRetrospective StudiesConceptsIL-6/ILInterleukin-6Skeletal sensitivityPerimenopausal periodPrimary hyperparathyroidismPerimenopausal womenCytokine systemInterleukin-6 soluble receptorSerum IL-6 valuesEstrogen-deficient stateUrine N-telopeptideInterleukin-6/interleukinAction of PTHGroup of patientsIL-6 valuesSerum IL-6/ILEstrogen modulatesIL-6sRIL-6sR.Perimenopausal groupUrine NTXPremenopausal womenSkeletal complicationsCytokine profileExaggerated releaseCirculating Levels of Interleukin-6 Soluble Receptor Predict Rates of Bone Loss in Patients with Primary Hyperparathyroidism
Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K. Circulating Levels of Interleukin-6 Soluble Receptor Predict Rates of Bone Loss in Patients with Primary Hyperparathyroidism. The Journal Of Clinical Endocrinology & Metabolism 2002, 87: 4946-4951. PMID: 12414855, DOI: 10.1210/jc.2001-011814.Peer-Reviewed Original ResearchConceptsBone lossIL-6sRTotal femurIL-6IL-6 soluble receptorPrimary hyperparathyroidism resultsYearly bone lossSubset of patientsUntreated hyperparathyroidismDisease activityPrimary hyperparathyroidismUpper tertileCytokine axisHyperparathyroidismSoluble receptorPatientsBiochemical markersClassical biochemical markersWhole groupFemurPredict rateGreater rateRecent studiesTertileGroup
2001
IL-6 negatively regulates IL-11 production in vitro and in vivo.
Nakchbandi I, Mitnick M, Masiukiewicz U, Sun B, Insogna K. IL-6 negatively regulates IL-11 production in vitro and in vivo. Endocrinology 2001, 142: 3850-6. PMID: 11517162, DOI: 10.1210/endo.142.9.8368.Peer-Reviewed Original ResearchConceptsIL-11 productionIL-6IL-11Bone resorptionOsteoclast formationIL-6 levelsIL-11 levelsFive-day infusionPTH excessPrimary hyperparathyroidismSerum levelsResorptive responseParathyroid adenomectomyPretreatment of cellsHuman PTHNonimmune serumPTHEffect of pretreatmentMRNA levelsSteady-state mRNA levelsPatientsCytokinesHuman osteoblast-like cellsResorptionSaos-2 cellsIL-6 Negatively Regulates IL-11 Production in Vitro and in Vivo
Nakchbandi I, Mitnick M, Masiukiewicz U, Sun B, Insogna K. IL-6 Negatively Regulates IL-11 Production in Vitro and in Vivo. Endocrinology 2001, 142: 3850-3856. DOI: 10.1210/en.142.9.3850.Peer-Reviewed Original ResearchCirculating levels of IL-6Levels of IL-6IL-11IL-6Circulating levelsBone resorptionSteady state mRNA levelsOsteoclast formationFive-day infusionHuman PTH-(1-84Pretreatment of cellsIL-11 levelsResponse to PTHIL-11 productionIncreased osteoclast formationIL-6 levelsPTH-(1-84Saos-2 cellsParathyroid adenomectomyDown-regulationProduction in vitroPrimary hyperparathyroidismPTH excessProduction in vivoSerum levelsChapter 25 Cytokines in Primary Hyperparathyroidism
Nakchbandi I, Grey A, Masiukiewicz U, Mitnick M, Insogna K. Chapter 25 Cytokines in Primary Hyperparathyroidism. 2001, 411-421. DOI: 10.1016/b978-012098651-4/50027-4.ChaptersOsteoclast differentiation factorParathyroid hormonePrimary hyperparathyroidismImmune cell functionColony-stimulating factorResorptive actionSevere inflammationBone resorptionInterleukin-6Resorptive effectsCatabolic cytokinesCytokinesMature osteoclastsPleiotropic actionsImportant mediatorKey mediatorCell functionDifferentiation factorHyperparathyroidismOsteoclastogenesisMediatorsHematopoietic microenvironmentInflammationInfectionCell communication
1999
A Role for Interleukin-6 in Parathyroid Hormone-Induced Bone Resorption in Vivo
Grey A, Mitnick M, Masiukiewicz U, Sun B, Rudikoff S, Jilka R, Manolagas S, Insogna K. A Role for Interleukin-6 in Parathyroid Hormone-Induced Bone Resorption in Vivo. Endocrinology 1999, 140: 4683-4690. PMID: 10499526, DOI: 10.1210/endo.140.10.7036.Peer-Reviewed Original ResearchConceptsParathyroid hormoneInterleukin-6Bone resorptionBiochemical markersPTH infusionEffect of PTHIL-6 productionCytokine interleukin-6Bone-resorbing cellsRelease of calciumPrimary hyperparathyroidismSerum levelsOsteoblastic cellsParacrine agentsCalcium homeostasisExperimental animalsPermissive roleChronic deficiencyResorptionImportant mediatorSystemic levelsBone formationRegulatory effectsInfusionMarkers
1998
The role of parathyroid hormone in the pathogenesis, prevention and treatment of postmenopausal osteoporosis
Masiukiewicz US, Insogna KL. The role of parathyroid hormone in the pathogenesis, prevention and treatment of postmenopausal osteoporosis. Aging Clinical And Experimental Research 1998, 10: 232-239. PMID: 9801733, DOI: 10.1007/bf03339657.Peer-Reviewed Original ResearchConceptsParathyroid hormonePostmenopausal womenPrimary hyperparathyroidismBone lossSecondary hyperparathyroidismAnabolic therapyPostmenopausal osteoporosisBone massVitamin D. Parathyroid hormoneDaily subcutaneous administrationRecent therapeutic trialsVitamin D metabolismTrabecular bone massTherapeutic trialsD metabolismBone turnoverBone resorptionSurgical correctionSubcutaneous administrationHyperparathyroidismVivo effectsSingle agentTissue responsivenessSustained increaseCortical sites
1996
Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption--a clinical research center study
Grey A, Mitnick MA, Shapses S, Ellison A, Gundberg C, Insogna K. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption--a clinical research center study. The Journal Of Clinical Endocrinology & Metabolism 1996, 81: 3450-3454. PMID: 8855783, DOI: 10.1210/jcem.81.10.8855783.Peer-Reviewed Original ResearchConceptsPrimary hyperparathyroidismUntreated primary hyperparathyroidismSerum type ITumor necrosisInterleukin-6Bone resorptionSerum levelsBiochemical markersSerum deoxypyridinolineUrinary deoxypyridinolineUrinary pyridinolineBone lossCarboxyterminal telopeptideSoluble receptorClinical research center studyControl valuesNormal parathyroid functionSuccessful surgical treatmentBone-resorbing cytokinesInterleukin-1 betaType IIntact PTHParathyroid functionSurgical treatmentCenter study
1986
Primary hyperparathyroidism in a dog: biochemical, bone histomorphometric, and pathologic findings.
Weir EC, Norrdin RW, Barthold SW, Meuten DJ, Pond MJ, Insogna KL. Primary hyperparathyroidism in a dog: biochemical, bone histomorphometric, and pathologic findings. Journal Of The American Veterinary Medical Association 1986, 189: 1471-4. PMID: 3804843.Peer-Reviewed Original ResearchConceptsPrimary hyperparathyroidismEighth postoperative dayBlood biochemical findingsParathyroid gland adenomaIliac crest biopsiesBone histomorphometricRenal failurePostoperative daySurgical explorationPathologic findingsHistologic diagnosisClinical signsOval massCrest biopsiesGland adenomaBlunt dissectionClearance studiesBiochemical findingsHyperparathyroidismHistomorphometric analysisDiagnosisDogsTrabecular boneVeterinary cliniciansBone
1985
Sensitivity of the Parathyroid Hormone–1, 25-Dihydroxyvitamin D Axis to Variations in Calcium Intake in Patients with Primary Hyperparathyroidism
Insogna K, Mitnick M, Stewart A, Burtis W, Mallette L, Broadus A. Sensitivity of the Parathyroid Hormone–1, 25-Dihydroxyvitamin D Axis to Variations in Calcium Intake in Patients with Primary Hyperparathyroidism. New England Journal Of Medicine 1985, 313: 1126-1130. PMID: 2995810, DOI: 10.1056/nejm198510313131805.Peer-Reviewed Original ResearchConceptsPrimary hyperparathyroidismParathyroid functionParathyroid hormone-vitamin D axisAutonomous parathyroid functionNephrogenous cyclic AMPImmunoreactive parathyroid hormoneNormal dietary intakeExtracellular calcium concentrationParathyroid hormone 1Calcium excretionCalcium intakeUnselected patientsSerum levelsParathyroid hormoneDihydroxyvitamin DDietary calciumPlasma levelsDietary intakePhysiologic amountsHyperparathyroidismPatientsHormone 1Calcium concentrationCyclic AMPSignificant reduction